Bioactive glass as dead space management following debridement of type 3 chronic osteomyelitis
- 29 Downloads
Chronic osteomyelitis is a challenging condition to treat and although no exact treatment guidelines exist, the surgical management strategy includes wide resection of necrotic and infected bone followed by dead space management. This study evaluates the use of bioactive glass as a single-stage procedure for dead space management following surgical debridement.
A consecutive series of 24 patients with Cierny-Mader type 3 osteomyelitis, treated between March 2016 and June 2018, were identified and evaluated retrospectively. Patients were managed with bioactive glass as dead space management following surgical debridement.
Of the patients who completed more than 12 months follow-up, all fourteen (100%) showed complete resolution of symptoms. Of the remaining ten patients with less than 12 months follow-up, eight had complete resolution of symptoms. Therefore, a preliminary result of 22 out of 24 patients (91.65%) had resolution of symptoms following debridement and dead space management with bioactive glass. One patient experienced a complication related to the use of bioactive glass. This manifested as prolonged serous wound drainage that resolved with local wound care.
The use of bioactive glass appears to be effective for dead space management following debridement of anatomical type 3 chronic osteomyelitis of the appendicular skeleton.
KeywordsChronic osteomyelitis Bioactive glass Dead space management
- 1.Hall BB, Rosenblatt JE, Fitzgerald RH Jr (1984) Anaerobic septic arthritis and osteomyelitis. Orthop Clin North Am 15(3):505–516Google Scholar
- 10.Cierny G 3rd, Mader JT, Penninck JJ (2003) A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res (414):p. 7-24Google Scholar
- 14.Marais LC, Ferreira N, Aldous C, Le Roux TLB (2014) The mangement of chronic osteomyelitis: Part II - Principles of post-infective reconstruction and antibiotic therapy. SA Orthop J 13(3):32–39Google Scholar
- 16.Marais LC, Ferreira N, Aldous C, Le Roux TLB (2014) The managemet of chronic osteomyelitis. Part I Diagnostic work-up and surgical principles. SA Orthop J 13(2):42–48Google Scholar
- 23.Wilson J, Clark AE, Hall M, Hench LL (1993) Tissue response to Bioglass endosseous ridge maintenance implants. J Oral Implantol 19(4):295–302Google Scholar
- 33.Lindfors N, Geurts J, Drago L, Arts JJ, Juutilainen V, Hyvonen P, Suda AJ, Domenico A, Artiaco S, Alizadeh C, Brychcy A, Bialecki J, Romano CL (2017) Antibacterial bioactive glass, S53P4, for chronic bone infections - a multinational study. Adv Exp Med Biol 971:81–92CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Geurts J, Vranken T, Gabriels F, Arts JJ, Moh P (2018) Contemporary treatment of chronic osteomyelitis: implementation in low- and middle-income countries. SA Orthop J 17(2):40–43Google Scholar
- 41.Lindfors NC, Koski I, Heikkila JT, Mattila K, Aho AJ (2010) A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res B Appl Biomater 94(1):157–164Google Scholar
- 47.Corona PS, Espinal L, Rodriguez-Pardo D, Pigrau C, Larrosa N, Flores X (2014) Antibiotic susceptibility in gram-positive chronic joint arthroplasty infections: increased aminoglycoside resistance rate in patients with prior aminoglycoside-impregnated cement spacer use. J Arthroplast 29(8):1617–1621CrossRefGoogle Scholar
- 50.Geurts J, Vranken T, Chris Arts JJ (2016) Treatment of osteomyelitis by means of bioactive glass - initial experience in the Netherlands. Nederlands Tijdschrift voor Orthopaedie, Vol 23, Nr 2, June 2016Google Scholar
- 52.Schlickewei CW, Yarar S, Rueger JM (2014) Eluding antibiotic bone graft substitutes for the treatment of osteomyelitis in long bones. A review: evidence for their use. Orthop Res Rev 6:71–79Google Scholar
- 53.Romano CL, Logoluso N, Meani E, Romano D, De Vecchi E, Vassena C, Drago L (2014). A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis. Bone Joint J 2014; 96-BGoogle Scholar
- 54.Jia WT, Fu Q, Huang WH, Zhang CQ, Rahaman MN (2015) Comparison of borate bioactive glass and calcium sulfate as implants for the local delivery of teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus-induced osteomyelitis in a rabbit model. Antimicrob Agents Chemother 59(12):7571–7580PubMedCentralCrossRefPubMedGoogle Scholar